Literature DB >> 19748892

A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.

Tali Fishman-Jacob1, Lydia Reznichenko, Moussa B H Youdim, Silvia A Mandel.   

Abstract

The aim of this study was to develop a new model of sporadic Parkinson disease (PD) based on silencing of the SKP1A gene, a component of the ubiquitin-proteasome/E3 ligase complex, Skp1, Cullin 1, F-box protein, which was found to be highly decreased in the substantia nigra of sporadic PD patients. Initially, an embryonic mouse substantia nigra-derived cell line (SN4741 cells) was infected with short hairpin RNA lentiviruses encoding the murine transcript of the SKP1A gene or with scrambled vector. SKP1A silencing resulted in increased susceptibility to neuronal damages induced by the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium ion and serum starvation, in parallel with a decline in the expression of the dopaminergic markers, dopamine transporter and vesicular monoamine transporter-2. SKP1A-deficient cells presented a delay in completion of the cell cycle and the inability to arrest at the G(0)/G(1) phase when induced to differentiate. Instead, the cells progressed through S phase, developing rounded aggregates with characteristics of aggresomes including immunoreactivity for gamma-tubulin, alpha-synuclein, ubiquitin, tyrosine hydroxylase, Hsc-70 (70-kDa heat shock cognate protein), and proteasome subunit, and culminating in a lethal phenotype. Conversely, stably enforced expression of wild type SKP1A duplicated the survival index of naïve SN4741 cells under proteasomal inhibition injury, suggesting a new structural role of SKP1 in dopaminergic neuronal function, besides its E3 ligase activity. These results link, for the first time, SKP1 to dopamine neuronal function and survival, suggesting an essential role in sporadic PD. In summary, this new model has reproduced to a significant extent the molecular alterations described in sporadic PD at the cellular level, implicating Skp1 as a potential modifier in sporadic PD neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748892      PMCID: PMC2781700          DOI: 10.1074/jbc.M109.034223

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations.

Authors:  Cheng Wang; Jeanne M M Tan; Michelle W L Ho; Norazean Zaiden; Siew Heng Wong; Constance L C Chew; Pei Woon Eng; Tit Meng Lim; Ted M Dawson; Kah Leong Lim
Journal:  J Neurochem       Date:  2005-04       Impact factor: 5.372

2.  Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.

Authors:  John F Staropoli; Caroline McDermott; Cécile Martinat; Brenda Schulman; Elena Demireva; Asa Abeliovich
Journal:  Neuron       Date:  2003-03-06       Impact factor: 17.173

3.  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

Authors:  Michael A Hauser; Yi-Ju Li; Hong Xu; Maher A Noureddine; Yujun S Shao; Steven R Gullans; Clemens R Scherzer; Roderick V Jensen; Adam C McLaurin; Jason R Gibson; Burton L Scott; Rita M Jewett; Judith E Stenger; Donald E Schmechel; Christine M Hulette; Jeffery M Vance
Journal:  Arch Neurol       Date:  2005-06

4.  Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone.

Authors:  D L Stenoien; C J Cummings; H P Adams; M G Mancini; K Patel; G N DeMartino; M Marcelli; N L Weigel; M A Mancini
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

5.  Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.

Authors:  Ning Zheng; Brenda A Schulman; Langzhou Song; Julie J Miller; Philip D Jeffrey; Ping Wang; Claire Chu; Deanna M Koepp; Stephen J Elledge; Michele Pagano; Ronald C Conaway; Joan W Conaway; J Wade Harper; Nikola P Pavletich
Journal:  Nature       Date:  2002-04-18       Impact factor: 49.962

6.  Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.

Authors:  Helen C Ardley; Gina B Scott; Stephen A Rose; Nancy G S Tan; Alexander F Markham; Philip A Robinson
Journal:  Mol Biol Cell       Date:  2003-08-22       Impact factor: 4.138

7.  Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit.

Authors:  Rick F Nelson; Kevin A Glenn; Yuzhou Zhang; Hsiang Wen; Tina Knutson; Cynthia M Gouvion; Barbara K Robinson; Zouping Zhou; Baoli Yang; Richard J H Smith; Henry L Paulson
Journal:  J Neurosci       Date:  2007-05-09       Impact factor: 6.167

8.  Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.

Authors:  M Gassen; A Gross; M B Youdim
Journal:  Mov Disord       Date:  1998-07       Impact factor: 10.338

9.  CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.

Authors:  Yuzuru Imai; Mariko Soda; Shigetsugu Hatakeyama; Takumi Akagi; Tsutomu Hashikawa; Kei Ichi Nakayama; Ryosuke Takahashi
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  Human class I alcohol dehydrogenases catalyze the interconversion of alcohols and aldehydes in the metabolism of dopamine.

Authors:  G Mårdh; B L Vallee
Journal:  Biochemistry       Date:  1986-11-18       Impact factor: 3.162

View more
  13 in total

1.  Gastrodia elata Blume (tianma) mobilizes neuro-protective capacities.

Authors:  Arulmani Manavalan; Umamaheswari Ramachandran; Husvinee Sundaramurthi; Manisha Mishra; Siu Kwan Sze; Jiang-Miao Hu; Zhi Wei Feng; Klaus Heese
Journal:  Int J Biochem Mol Biol       Date:  2012-06-03

2.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 3.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 4.  Of Pesticides and Men: a California Story of Genes and Environment in Parkinson's Disease.

Authors:  Beate R Ritz; Kimberly C Paul; Jeff M Bronstein
Journal:  Curr Environ Health Rep       Date:  2016-03

5.  A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.

Authors:  Ye Han; Christina E Khodr; Mohan K Sapru; Jyothi Pedapati; Martha C Bohn
Journal:  Brain Res       Date:  2011-02-19       Impact factor: 3.252

Review 6.  Emerging roles of epigenetic mechanisms in Parkinson's disease.

Authors:  Ehsan Habibi; Ali Masoudi-Nejad; Hamid Mostafavi Abdolmaleky; Stephen J Haggarty
Journal:  Funct Integr Genomics       Date:  2011-09-04       Impact factor: 3.410

7.  Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.

Authors:  Edna Grünblatt; Josefine Ruder; Camelia Maria Monoranu; Peter Riederer; Moussa Bh Youdim; Silvia A Mandel
Journal:  Neurotox Res       Date:  2017-12-07       Impact factor: 3.911

8.  Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson׳s disease.

Authors:  Shannon L Rhodes; Arthur G Fitzmaurice; Myles Cockburn; Jeff M Bronstein; Janet S Sinsheimer; Beate Ritz
Journal:  Environ Res       Date:  2013-08-27       Impact factor: 6.498

9.  Dysregulation of core components of SCF complex in poly-glutamine disorders.

Authors:  S Bhutani; A Das; M Maheshwari; S C Lakhotia; N R Jana
Journal:  Cell Death Dis       Date:  2012-11-22       Impact factor: 8.469

10.  New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment.

Authors:  R Andrew Tasker; Amber L Adams-Marriott; Christopher A Shaw
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.